Low-molecular-weight heparin in patients with acute ST-segment elevation myocardial infarction
1Division of Cardiology, Cardiac Catheterization Laboratory, Newark Beth Israel Center, Newark, NJ 07112, USA. marcohen@sbhcs.com
Insights
Rapid pharmacological reperfusion therapy is crucial for acute ST-segment elevation myocardial infarction (STEMI) patients. Simpler fibrinolytic and antithrombin regimens, like tenecteplase with enoxaparin, may improve outcomes compared to unfractionated heparin.
Area of Science:
- Cardiology
- Emergency Medicine
- Pharmacology
Background:
- Acute ST-segment elevation myocardial infarction (STEMI) requires rapid restoration of blood flow.
- Many STEMI patients do not reach hospitals for primary percutaneous coronary intervention.
- Pharmacological reperfusion therapy is essential for these patients.
Purpose of the Study:
- To evaluate the efficacy and ease of administration of pharmacological reperfusion therapies for STEMI.
- To compare simpler fibrinolytic and antithrombin regimens with traditional ones.
Main Methods:
- Review of pharmacological reperfusion strategies for STEMI.
- Analysis of fibrinolytic therapy combined with adjunctive antithrombin agents.
- Comparison of tenecteplase with enoxaparin versus unfractionated heparin regimens.
Main Results:
- Prompt reperfusion significantly limits infarct size and improves survival in STEMI.
- Simpler and quicker administration of pharmacological reperfusion therapy can lead to better outcomes.
- Tenecteplase with enoxaparin may be more efficacious and easier to use than unfractionated heparin-based regimens.
Conclusions:
- Optimizing pharmacological reperfusion is key for STEMI management in hospitals without primary PCI capabilities.
- Simpler, faster fibrinolytic and antithrombin therapies hold promise for improved STEMI patient outcomes.
- Tenecteplase and enoxaparin represent a potentially superior alternative for pharmacological reperfusion in STEMI.
Abstract:
One of the primary goals of physicians treating patients presenting to a hospital with acute ST-segment elevation myocardial infarction is to restore the flow of blood in the infarct-related artery as quickly as possible. Prompt and successful reperfusion limits the size of the myocardial infarction, reduces left ventricular dysfunction, and improves the patient's chance of survival. Approximately two thirds of patients with ST-segment elevation myocardial infarction do not present to a hospital capable of conducting urgent direct percutaneous coronary intervention or cardiac surgery when it is needed. They must receive pharmacological reperfusion therapy, a combination of fibrinolytic, antiplatelet, and anticoagulant drugs. Earlier and simpler administration of pharmacological reperfusion therapy could result in significantly improved outcomes. Fibrinolytic therapy, in combination with adjunctive antithrombin therapy that is simpler and quicker to administer (e.g., tenecteplase with enoxaparin), may be more efficacious and easier to use than regimens involving unfractionated heparin.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:30Acute Coronary Syndrome I: Introduction
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:29Venous Thrombosis III: Interprofessional Care
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care